{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:10:21Z","timestamp":1793812221147,"version":"4.6.1"},"reference-count":147,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/lgt.0b013e31824ca9d5","type":"journal-article","created":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T09:05:27Z","timestamp":1331715927000},"page":"175-204","source":"Crossref","is-referenced-by-count":288,"title":["American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer"],"prefix":"10.1097","volume":"16","author":[{"given":"Debbie","family":"Saslow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herschel W.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Killackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini L.","family":"Kulasingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco A. R.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann T.","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G.","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wilbur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Wentzensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levi S.","family":"Downs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Barbara","family":"Moscicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Stoler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Schiffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E.","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan R.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210126","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3322\/canjclin.52.6.342","article-title":". American Cancer Society guideline for the early detection of cervical neoplasia and cancer.","volume":"52","author":"Saslow","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"R2-5-20210126","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/LGT.0b013e3181585870","article-title":"2006 consensus guidelines for the management of women with abnormal cervical screening tests.","volume":"11","author":"Wright","year":"2007","journal-title":"J Low Genit Tract Dis"},{"key":"R3-5-20210126","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-#","article-title":"International incidence rates of invasive cervical cancer before cytological screening.","volume":"71","author":"Gustafsson","year":"1997","journal-title":"Int J Cancer"},{"key":"R4-5-20210126","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1023\/A:1018435522475","article-title":"International incidence rates of invasive cervical cancer after introduction of cytological screening.","volume":"8","author":"Gustafsson","year":"1997","journal-title":"Cancer Causes Control"},{"issue":"suppl 3","key":"R5-5-20210126","first-page":"S311","article-title":"Chapter 2: The burden of HPV-related cancers.","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"key":"R6-5-20210126","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012.","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R8-5-20210126","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":". Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"R9-5-20210126","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":". Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"R10-5-20210126","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":". Epidemiologic classification of human papillomavirus types associated with cervical cancer.","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"R11-5-20210126","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMp020178","article-title":"Adding a test for human papillomavirus DNA to cervical-cancer screening.","volume":"348","author":"Wright","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-5-20210126","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer.","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"R13-5-20210126","first-page":"55","article-title":"Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002.","volume":"1-","author":"Mosher","year":"2005","journal-title":"Adv Data"},{"key":"R14-5-20210126","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/516784","article-title":"A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion.","volume":"195","author":"Plummer","year":"2007","journal-title":"J Infect Dis"},{"key":"R15-5-20210126","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jnci\/djn044","article-title":". Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.","volume":"100","author":"Rodriguez","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R16-5-20210126","doi-asserted-by":"crossref","first-page":"b2569","DOI":"10.1136\/bmj.b2569","article-title":". Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study.","volume":"339","author":"Castle","year":"2009","journal-title":"BMJ"},{"key":"R17-5-20210126","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.","volume":"102","author":"Kjaer","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R18-5-20210126","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":". Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol"},{"key":"R19-5-20210126","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/AOG.0b013e3181e3e719","article-title":". The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer.","volume":"116","author":"Castle","year":"2010","journal-title":"Obstet Gynecol"},{"key":"R20-5-20210126","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0002-9378(03)00418-6","article-title":"Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance.","volume":"188","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R21-5-20210126","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jnci\/95.1.46","article-title":". Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.","volume":"95","author":"Sherman","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R22-5-20210126","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":". Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"key":"R23-5-20210126","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/1055-9965.EPI-11-0206","article-title":". A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.","volume":"20","author":"Schiffman","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R26-5-20210126","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ypmed.2007.06.007","article-title":"Process of care failures in invasive cervical cancer: systematic review and meta-analysis.","volume":"45","author":"Spence","year":"2007","journal-title":"Prev Med"},{"key":"R27-5-20210126","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/cncr.25065","article-title":". Cervical cancer prevention: new tools and old barriers.","volume":"116","author":"Scarinci","year":"2010","journal-title":"Cancer"},{"key":"R28-5-20210126","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1309\/PT3PNC1QL2F4D2VL","article-title":"The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report.","volume":"127","author":"Castle","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R29-5-20210126","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/AOG.0b013e31818f5008","article-title":"Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2.","volume":"113","author":"Castle","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R30-5-20210126","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-04-2599","article-title":". Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype.","volume":"11","author":"Trimble","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R31-5-20210126","doi-asserted-by":"crossref","first-page":"a1284","DOI":"10.1136\/bmj.a1284","article-title":". Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis.","volume":"337","author":"Arbyn","year":"2008","journal-title":"BMJ"},{"key":"R32-5-20210126","first-page":"151","article-title":"Screening for cervical cancer: will women accept less Am J M","volume":"118","author":"Sirovich","year":"2005","journal-title":"ed"},{"key":"R33-5-20210126","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/LGT.0b013e3181cec411","article-title":"Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women.","volume":"14","author":"Moscicki","year":"2010","journal-title":"J Low Genit Tract Dis"},{"key":"R34-5-20210126","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/AOG.0b013e3181c6f8a4","article-title":"109: Cervical cytology screening.","volume":"114","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R35-5-20210126","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.AOG.0000296488.85807.b3","article-title":"Liquid compared with conventional cervical cytology: a systematic review and meta-analysis.","volume":"111","author":"Arbyn","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R36-5-20210126","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.2009.1569","article-title":". Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial.","volume":"302","author":"Siebers","year":"2009","journal-title":"JAMA"},{"key":"R37-5-20210126","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":". Overview of the European and North American studies on HPV testing in primary cervical cancer screening.","volume":"119","author":"Cuzick","year":"2006","journal-title":"Int J Cancer"},{"key":"R38-5-20210126","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa071430","article-title":". Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.","volume":"357","author":"Mayrand","year":"2007","journal-title":"N Engl J Med"},{"key":"R39-5-20210126","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa073204","article-title":". Human papillomavirus and Papanicolaou tests to screen for cervical cancer.","volume":"357","author":"Naucler","year":"2007","journal-title":"N Engl J Med"},{"key":"R40-5-20210126","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(07)61450-0","article-title":". Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.","volume":"370","author":"Bulkmans","year":"2007","journal-title":"Lancet"},{"key":"R41-5-20210126","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":". Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol"},{"key":"R42-5-20210126","doi-asserted-by":"crossref","first-page":"c1804","DOI":"10.1136\/bmj.c1804","article-title":". Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.","volume":"340","author":"Anttila","year":"2010","journal-title":"BMJ"},{"key":"R43-5-20210126","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","article-title":"Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.","volume":"12","author":"Castle","year":"2011","journal-title":"Lancet Oncol"},{"key":"R44-5-20210126","first-page":"1197","article-title":"HPV for cervical cancer screening: is the era of the molecular pap smear upon us J Histochem C","volume":"49","author":"Stoler","year":"2001","journal-title":"ytochem"},{"key":"R45-5-20210126","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1309\/BA43HMCAJ26VWQH3","article-title":"Interlaboratory reliability of Hybrid Capture 2.","volume":"122","author":"Castle","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"R46-5-20210126","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1309\/84E5WHJQHK83BGQD","article-title":". Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting.","volume":"124","author":"Carozzi","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"R47-5-20210126","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":". Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.","volume":"124","author":"Meijer","year":"2009","journal-title":"Int J Cancer"},{"key":"R48-5-20210126","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1309\/RNF3C01JKADQCLKP","article-title":"The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays.","volume":"127","author":"Stoler","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R49-5-20210126","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1309\/AJCPRI8XPQUEAA3K","article-title":"Special commentary: patient safety and the next generation of HPV DNA tests.","volume":"134","author":"Kinney","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"R50-5-20210126","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcv.2004.12.011","article-title":"The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBCHPV studies.","volume":"33","author":"Cubie","year":"2005","journal-title":"J Clin Virol"},{"key":"R51-5-20210126","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":". Going from evidence to recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R52-5-20210126","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/bmj.39504.506319.80","article-title":". Incorporating considerations of resources use into grading recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R53-5-20210126","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is quality of evidence and why is it important to clinicians","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R54-5-20210126","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":". GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R55-5-20210126","doi-asserted-by":"crossref","first-page":"a744","DOI":"10.1136\/bmj.a744","article-title":". Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive.","volume":"337","author":"Jaeschke","year":"2008","journal-title":"BMJ"},{"key":"R56-5-20210126","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":". Grading quality of evidence and strength of recommendations for diagnostic tests and strategies.","volume":"336","author":"Schunemann","year":"2008","journal-title":"BMJ"},{"issue":"RR-4","key":"R57-5-20210126","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.","volume":"58","author":"Kaplan","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"R58-5-20210126","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/LGT.0b013e3181d95ad6","article-title":"Practice improvement in cervical screening and management: symposium on management of cervical abnormalities in adolescents and young women.","volume":"14","author":"Castle","year":"2010","journal-title":"J Low Genit Tract Dis"},{"key":"R59-5-20210126","doi-asserted-by":"crossref","first-page":"b2968","DOI":"10.1136\/bmj.b2968","article-title":"Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data.","volume":"339","author":"Sasieni","year":"2009","journal-title":"BMJ"},{"key":"R60-5-20210126","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.57.1.7","article-title":". American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors.","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"RR-2","key":"R61-5-20210126","first-page":"1","article-title":"Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"R62-5-20210126","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1001\/archinte.168.17.1881","article-title":"Trade-offs in cervical cancer prevention: balancing benefits and risks.","volume":"168","author":"Stout","year":"2008","journal-title":"Arch Intern Med"},{"key":"R64-5-20210126","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/bjc.1996.196","article-title":"Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group.","volume":"73","author":"Sasieni","year":"1996","journal-title":"Br J Cancer"},{"key":"R65-5-20210126","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.bjc.6600974","article-title":"Benefit of cervical screening at different ages: evidence from the UK audit of screening histories.","volume":"89","author":"Sasieni","year":"2003","journal-title":"Br J Cancer"},{"key":"R66-5-20210126","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":". Prevalence of HPV infection among females in the United States.","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"R67-5-20210126","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1086\/320696","article-title":". Determinants of genital human papillomavirus detection in a US population.","volume":"183","author":"Peyton","year":"2001","journal-title":"J Infect Dis"},{"key":"R68-5-20210126","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/sj.bjc.6602002","article-title":"The predicted effect of changes in cervical screening practice in the UK: results from a modelling study.","volume":"91","author":"Canfell","year":"2004","journal-title":"Br J Cancer"},{"key":"R69-5-20210126","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/01.AOG.0000120143.50098.c7","article-title":"Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.","volume":"103","author":"Goldie","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R70-5-20210126","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/jnci\/dji162","article-title":"Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.","volume":"97","author":"Kim","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R71-5-20210126","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00006250-200305000-00043","article-title":"Screening interval and risk of invasive squamous cell cervical cancer.","volume":"101","author":"Miller","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R72-5-20210126","first-page":"228","article-title":"Incidence of cervical intraepithelial neoplasia grade III, and cancer of the cervix uteri following a negative Pap-smear in an opportunistic screening.","volume":"77","author":"Gram","year":"1998","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R73-5-20210126","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJMoa035419","article-title":". Risk of cervical cancer associated with extending the interval between cervical-cancer screenings.","volume":"349","author":"Sawaya","year":"2003","journal-title":"N Engl J Med"},{"key":"R74-5-20210126","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","article-title":". Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.","volume":"12","author":"Katki","year":"2011","journal-title":"Lancet Oncol"},{"key":"R76-5-20210126","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/1055-9965.EPI-05-0231","article-title":". Incidence trends of adenocarcinoma of the cervix in 13 European countries.","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R77-5-20210126","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/cncr.20064","article-title":"Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000.","volume":"100","author":"Wang","year":"2004","journal-title":"Cancer"},{"key":"R78-5-20210126","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.AOG.0000109426.82624.f8","article-title":". Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.","volume":"103","author":"Wright","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R79-5-20210126","first-page":"977","article-title":"Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending Arch Intern M","volume":"17","author":"Saraiya","year":"2010","journal-title":"ed"},{"issue":"suppl 3","key":"R80-5-20210126","first-page":"S378","article-title":"Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.","volume":"24","author":"Arbyn","year":"2006","journal-title":"Vaccine"},{"key":"R81-5-20210126","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1001\/jama.285.11.1500","article-title":"Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study.","volume":"285","author":"Stoler","year":"2001","journal-title":"JAMA"},{"key":"R82-5-20210126","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(09)70156-1","article-title":". HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.","volume":"10","author":"Kitchener","year":"2009","journal-title":"Lancet Oncol"},{"key":"R83-5-20210126","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(09)70246-3","article-title":"Further analysis of the ARTISTIC trial.","volume":"10","author":"Sasieni","year":"2009","journal-title":"Lancet Oncol"},{"key":"R84-5-20210126","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF03404377","article-title":"Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada.","volume":"101","author":"Vijayaraghavan","year":"2010","journal-title":"Can J Public Health"},{"key":"R85-5-20210126","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ygyno.2006.08.053","article-title":"Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies.","volume":"104","author":"Koliopoulos","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R86-5-20210126","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/bjc.1995.172","article-title":"Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit.","volume":"71","author":"Mitchell","year":"1995","journal-title":"Br J Cancer"},{"key":"R87-5-20210126","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/sj.bjc.6601754","article-title":"Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence.","volume":"90","author":"Zappa","year":"2004","journal-title":"Br J Cancer"},{"key":"R88-5-20210126","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ijc.22357","article-title":"Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies.","volume":"120","year":"2007","journal-title":"Int J Cancer"},{"key":"R89-5-20210126","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jnci\/djj067","article-title":". Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.","volume":"98","author":"Castellsague","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"R90-5-20210126","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0002-9378(03)00413-7","article-title":"A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations.","volume":"188","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R91-5-20210126","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ijc.24752","article-title":". Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology.","volume":"126","author":"Maucort-Boulch","year":"2010","journal-title":"Int J Cancer"},{"key":"R92-5-20210126","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":". The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.","volume":"97","author":"Khan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R93-5-20210126","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1309\/AJCPTUS5EXAS6DKZ","article-title":"Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV Cytology-Negative Results.","volume":"136","author":"Wright","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"R94-5-20210126","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/jnci\/djr283","article-title":". Persistence of type-specific Human papillomavirus infection and increased long-term risk of cervical cancer.","volume":"103","author":"Chen","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R95-5-20210126","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn510","article-title":"Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.","volume":"101","author":"Wheeler","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R96-5-20210126","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication.","volume":"128","author":"Li","year":"2011","journal-title":"Int J Cancer"},{"key":"R98-5-20210126","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0140-6736(03)14955-0","article-title":". Management of women who test positive for high-risk types of human papillomavirus: the HART study.","volume":"362","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"key":"R99-5-20210126","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1309\/AJCPAZV88VIFZSFD","article-title":". High-risk HPV testing in women 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up.","volume":"133","author":"Thrall","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"R100-5-20210126","doi-asserted-by":"crossref","first-page":"10630","DOI":"10.1158\/0008-5472.CAN-06-1057","article-title":". The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period.","volume":"66","author":"Kjaer","year":"2006","journal-title":"Cancer Res"},{"key":"R101-5-20210126","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z","article-title":". PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears.","volume":"68","author":"Rozendaal","year":"1996","journal-title":"Int J Cancer"},{"key":"R102-5-20210126","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.bjc.6602049","article-title":". Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort.","volume":"91","author":"Peto","year":"2004","journal-title":"Br J Cancer"},{"key":"R103-5-20210126","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1309\/AJCPZ5JY6FCVNMOT","article-title":"High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study.","volume":"135","author":"Stoler","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"R104-5-20210126","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/01.AOG.0000263461.71732.40","article-title":"Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.","volume":"109","author":"Safaeian","year":"2007","journal-title":"Obstet Gynecol"},{"key":"R105-5-20210126","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/jnci\/dji186","article-title":"Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.","volume":"97","author":"Castle","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R106-5-20210126","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/AOG.0b013e3181996ffa","article-title":"Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting.","volume":"113","author":"Castle","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R107-5-20210126","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-148-7-200804010-00004","article-title":". Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005.","volume":"148","author":"Datta","year":"2008","journal-title":"Ann Intern Med"},{"key":"R108-5-20210126","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(08)70208-0","article-title":". Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.","volume":"9","author":"Carozzi","year":"2008","journal-title":"Lancet Oncol"},{"key":"R109-5-20210126","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/jnci\/djp367","article-title":". Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.","volume":"101","author":"Leinonen","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R110-5-20210126","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ejca.2011.01.008","article-title":". A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial.","volume":"47","author":"Kitchener","year":"2011","journal-title":"Eur J Cancer"},{"key":"R112-5-20210126","doi-asserted-by":"crossref","first-page":"e12724","DOI":"10.1371\/journal.pone.0012724","article-title":"Triage of women with minor cervical lesions: data suggesting a test and treat approach for HPV E6E7 mRNA testing.","volume":"5","author":"Sorbye","year":"2010","journal-title":"PLoS One"},{"issue":"suppl 10","key":"R113-5-20210126","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1002\/cncr.23747","article-title":"Total burden and incidence of in situ and invasive cervical carcinoma in Michigan, 1985-2003.","volume":"113","author":"Copeland","year":"2008","journal-title":"Cancer"},{"key":"R114-5-20210126","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jama.1986.03380030069030","article-title":"Gynecological care of elderly women. Another look at Papanicolaou smear testing.","volume":"256","author":"Mandelblatt","year":"1986","journal-title":"JAMA"},{"key":"R115-5-20210126","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006250-200008000-00012","article-title":"Frequency of cervical smear abnormalities within 3 years of normal cytology.","volume":"96","author":"Sawaya","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R116-5-20210126","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jnci\/dji115","article-title":". Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.","volume":"97","author":"Leyden","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R117-5-20210126","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jnci\/djp089","article-title":"Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study.","volume":"101","author":"Melnikow","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R118-5-20210126","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/ijc.21604","article-title":"Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia.","volume":"118","author":"Soutter","year":"2006","journal-title":"Int J Cancer"},{"key":"R119-5-20210126","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/jnci\/djq001","article-title":". Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 23: critical role of duration of infection.","volume":"102","author":"Rodriguez","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R121-5-20210126","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJM199611213352103","article-title":"Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease.","volume":"335","author":"Pearce","year":"1996","journal-title":"N Engl J Med"},{"key":"R122-5-20210126","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/0002-9378(95)90262-7","article-title":"Cytologic screening after hysterectomy for benign disease.","volume":"173","author":"Piscitelli","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"R123-5-20210126","first-page":"233","article-title":"Routine vaginal cuff smear testing in post-hysterectomy patients with benign uterine conditions: when is it indicated J Am Board Fam P","volume":"13","author":"Videlefsky","year":"2000","journal-title":"ract"},{"key":"R124-5-20210126","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0002-9378(99)70601-0","article-title":"The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. Am.","volume":"180","author":"Fox","year":"1999","journal-title":"J Obstet Gynecol"},{"key":"R125-5-20210126","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1471-0528.1992.tb14440.x","article-title":"Long term follow up of women after hysterectomy with a history of pre-invasive cancer of the cervix.","volume":"99","author":"Wiener","year":"1992","journal-title":"Br J Obstet Gynaecol"},{"key":"R126-5-20210126","first-page":"1117","article-title":"13 through 17 years-United States, 2010. MMWR.","volume":"60","year":"2011","journal-title":"Morb Mortal Wkly Rep"},{"key":"R127-5-20210126","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"R128-5-20210126","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1086\/522864","article-title":"Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.","volume":"196","year":"2007","journal-title":"J Infect Dis"},{"key":"R129-5-20210126","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"key":"R130-5-20210126","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":". The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"R131-5-20210126","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":". Impact of human papillomavirus (HPV)-6111618 vaccine on all HPV-associated genital diseases in young women.","volume":"102","author":"Munoz","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R132-5-20210126","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":". Efficacy of human papillomavirus (HPV)-1618 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"R133-5-20210126","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":". Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-1618 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet"},{"key":"R134-5-20210126","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/eurpub\/ckn064","article-title":". Long-term clinical impact of introducing a human papillomavirus 1618 AS04 adjuvant cervical cancer vaccine in Spain.","volume":"18","author":"Gauthier","year":"2008","journal-title":"Eur J Public Health"},{"key":"R135-5-20210126","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"key":"R136-5-20210126","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.bjc.6605528","article-title":"Predicted impact of vaccination against human papillomavirus 1618 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.","volume":"102","author":"Cuzick","year":"2010","journal-title":"Br J Cancer"},{"key":"R137-5-20210126","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost-effectiveness of male HPV vaccination in the United States.","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"key":"R138-5-20210126","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies.","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"R139-5-20210126","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000214924","article-title":"Economic evaluation of human papillomavirus vaccination in developed countries.","volume":"12","author":"Brisson","year":"2009","journal-title":"Public Health Genomics"},{"key":"R140-5-20210126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/00016340802566770","article-title":"The efficacy of HPV 1618 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.","volume":"88","author":"Sigurdsson","year":"2009","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R141-5-20210126","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":". Projected clinical benefits and cost-effectiveness of a human papillomavirus 1618 vaccine.","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R142-5-20210126","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.290.6.781","article-title":"Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.","volume":"290","author":"Kulasingam","year":"2003","journal-title":"JAMA"},{"key":"R143-5-20210126","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.bjc.6604162","article-title":"Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening.","volume":"98","author":"Coupe","year":"2008","journal-title":"Br J Cancer"},{"key":"R144-5-20210126","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1016\/j.ejca.2010.06.016","article-title":". Cost-effectiveness of human papillomavirus vaccination and screening in Spain.","volume":"46","author":"Diaz","year":"2010","journal-title":"Eur J Cancer"},{"key":"R145-5-20210126","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1071\/SH07043","article-title":". A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.","volume":"4","author":"Kulasingam","year":"2007","journal-title":"Sex Health"},{"key":"R146-5-20210126","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1016\/j.vaccine.2007.09.035","article-title":"Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S.","volume":"25","author":"Kulasingam","year":"2007","journal-title":"Vaccine"},{"key":"R147-5-20210126","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1017\/S0266462309090217","article-title":"Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.","volume":"25","author":"Thiry","year":"2009","journal-title":"Int J Technol Assess Health Care"},{"key":"R148-5-20210126","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jnci\/djn019","article-title":"Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.","volume":"100","author":"Goldhaber-Fiebert","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 3","key":"R149-5-20210126","first-page":"S3171","article-title":"Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.","volume":"24","author":"Franco","year":"2006","journal-title":"Vaccine"},{"key":"R150-5-20210126","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.arcmed.2009.06.003","article-title":"The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change.","volume":"40","author":"Franco","year":"2009","journal-title":"Arch Med Res"},{"key":"R151-5-20210126","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ijc.24000","article-title":"HPV1618 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness.","volume":"124","author":"Coupe","year":"2009","journal-title":"Int J Cancer"},{"key":"R153-5-20210126","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10552-011-9877-6","article-title":". The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions.","volume":"23","author":"Hariri","year":"2012","journal-title":"Cancer Causes Control"},{"key":"R156-5-20210126","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ypmed.2011.03.018","article-title":". Comparative community outreach to increase cervical cancer screening in the Mississippi Delta.","volume":"52","author":"Castle","year":"2011","journal-title":"Prev Med"},{"key":"R157-5-20210126","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2011.1800","article-title":". New American Cancer Society process for creating trustworthy cancer screening guidelines.","volume":"306","author":"Brawley","year":"2011","journal-title":"JAMA"},{"key":"R158-5-20210126","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(11)70296-0","article-title":". Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.","volume":"13","author":"Rijkaart","year":"2012","journal-title":"Lancet Oncol"}],"container-title":["Journal of Lower Genital Tract Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/LGT.0b013e31824ca9d5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:34:52Z","timestamp":1786048492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00128360-201207000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":147,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/lgt.0b013e31824ca9d5","relation":{},"ISSN":["1089-2591"],"issn-type":[{"value":"1089-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}